It was essential to determine that the fluctuations in the key components of the algorithm (such as an individual’s AFP, ALK and ALT values) do not adversely impact the performance of the Doylestown algorithm and falsely identify those who do not have HCC. This evidence concerns the gene GPT and hepatocellular carcinoma.